Contineum Therapeutics, Inc. Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss
Contineum Therapeutics, Inc. (CTNM) reported Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-07-30
- Contineum Therapeutics, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Contineum Therapeutics, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Contineum Therapeutics, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-12-31 was $6.00K.
- Contineum Therapeutics, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Contineum Therapeutics, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was $12.00K, a 140.00% increase from fiscal 2024.
- Contineum Therapeutics, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was $5.00K.
- Contineum Therapeutics, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was -$19.00K.
| Period end | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $0.00 10-Q · filed 2026-07-30 | $6.00K derived: sum of 3 quarters · filed 2026-07-30 | $6.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $6.00K derived: sum of 2 quarters · filed 2026-05-05 | $6.00K derived: sum of 3 quarters · filed 2026-05-05 | $10.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.00K derived: sum of 2 quarters · filed 2026-03-05 | $10.00K derived: sum of 3 quarters · filed 2026-07-30 | $12.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $4.00K derived: sum of 2 quarters · filed 2026-07-30 | $6.00K 10-Q · filed 2025-10-30 | $6.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $6.00K 10-Q · filed 2026-07-30 | $6.00K derived: sum of 3 quarters · filed 2026-07-30 | $11.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $2.00K 10-Q · filed 2026-05-05 | $2.00K derived: sum of 2 quarters · filed 2026-05-05 | $7.00K derived: sum of 3 quarters · filed 2026-05-05 | $7.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.00K derived: sum of 2 quarters · filed 2026-03-05 | $5.00K derived: sum of 3 quarters · filed 2026-03-05 | $5.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $5.00K derived: sum of 2 quarters · filed 2025-10-30 | $5.00K 10-Q · filed 2025-10-30 | $8.00K derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $3.00K derived: sum of 3 quarters · filed 2025-08-05 | $5.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $3.00K derived: sum of 2 quarters · filed 2025-05-14 | $5.00K derived: sum of 3 quarters · filed 2025-05-14 | $5.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $5.00K derived: sum of 2 quarters · filed 2025-03-06 | $5.00K derived: sum of 3 quarters · filed 2025-03-06 | -$19.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.00K derived: sum of 2 quarters · filed 2024-11-06 | -$22.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$24.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$24.00K 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |